BSX · News · 20261106N

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-11-06 · Importance null · Surprise null

S&P Global Ratings changed Boston Scientific’s outlook to negative from stable while affirming its ‘A-’ issuer credit and senior unsecured debt ratings. S&P warned that commercial headwinds across core product franchises could keep financial leverage stretched through 2028. The agency cited the balance-sheet burden of Boston Scientific’s pending $14.5 billion acquisition of Penumbra Inc.

Key facts

• S&P Global Ratings revised its outlook on Boston Scientific Corp. to negative from stable and affirmed its 'A-' issuer credit rating and senior unsecured debt rating. source